Launching on 21st November: Research in Dementia webinar series
Starting on the 21st November, ADI are running a 3 part webinar series, creating a unique opportunity for the general public and Alzheimer and dementia associations to engage directly with health and social care professionals and companies involved in dementia research and clinical trials.
The first webinar, “Let’s Talk About Dementia Research: Demystifying Trials, Access and Understanding” will build on the findings from a recent Generation Program global survey of 10,000 people and ADI’s World Alzheimer Report 2018 and start at the beginning: discussing everything from what is dementia research to the practicalities for clinicians ‘on the ground' and the lived exp
Follow-on webinars will drill down into issues that spark particular interest with our audience – both public and professionals, concluding with a look ahead at overcoming some of these barriers and hopes for the future.
The first webinar will be streamed at 1-2.30 pm GMT on 19th November.
For more information and to sign up to the event click here.
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Alzheimer's blogs from BMC
Alzheimer's Research & Therapy is affiliated with Alzheimer's Disease International (ADI), London, United Kingdom.
2017 Journal Metrics
50.0 days to first decision for reviewed manuscripts only
43.4 days to first decision for all manuscripts
123.9 days from submission to acceptance
29.2 days from acceptance to publication
720 Altmetric mentions